MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$17,570K
Free Cash flow
-$19,476K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Share-based compensation expense
Accrued expenses and other curre...
Proceeds received from sale of a...
Others
Negative Cash Flow Breakdown
Gain on sale of assets
Prepaid expenses and other curre...
Other assets
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-24,837
-23,283
-92,397
-61,545
Share-based compensation expense
3,965
4,113
4,745
1,986
Research and development license expense
-
-
80,000
-
Gain on sale of assets
1,770
-
-
-
Depreciation expense
66
64
54
28
Non-cash interest expense
0
0
0
0
Non-cash research and development expense related to paragon option agreement
-
-
0
0
Non-cash lease expense
101
97
95
94
Accounts payable-Nonrelated Party
1,496
-2,312
1,024
1,488
Accrued expenses and other current liabilities-Nonrelated Party
-
-
-
2,005
Accrued expenses and other current liabilities
2,974
-3,456
5,363
-
Related party accounts payable and other current liabilities-Related Party
0
-140
-6,133
1,090
Deferred revenue
0
-1,039
4,156
-
Deposit liability
-
-
5,000
-
Operating lease liability
-106
-101
-97
46
Accounts receivable
0
-18,000
18,000
-
Prepaid expenses and other current assets
1,013
937
4,165
-284
Other assets
339
-57
-37
-47
Net cash used in operating activities
-19,463
-8,937
-26,740
-17,539
Purchase of research and development license
0
8,000
72,000
-
Proceeds received from sale of assets
1,770
-
-
-
Purchases of property and equipment
13
147
193
586
Net cash used in investing activities
1,757
-8,147
-72,193
-586
Proceeds from the pre-closing financing, net
0
-
-20
-1,254
Proceeds from the private placement financing, net
-
-
178,880
-
Cash acquired in connection with the reverse recapitalization
0
-
0
0
Proceeds from early exercise of options
0
0
0
0
Proceeds from issuance of common stock
-
-
0
-
Proceeds from issuance of series seed convertible preferred stock
-
-
0
-
Proceeds from the issuance of notes payable, net of issuance costs
-
-
0
-
Repurchase of equity awards
0
0
-
-
Payment of deferred offering costs
144
6,945
0
-
Repurchase of equity awards
-
-
0
0
Proceeds from issuance of shares under employee stock purchase plan
280
-
-
-
Net cash (used in) provided by financing activities
136
-6,945
178,860
-1,254
Net (decrease) increase in cash, cash equivalents, and restricted cash
-17,570
-24,029
79,927
-19,379
Cash, cash equivalents, and restricted cash at beginning of period
189,270
213,299
133,372
34,766
Cash, cash equivalents, and restricted cash at end of period
171,700
189,270
213,299
133,372
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds received from
sale of assets
$1,770K
Proceeds from issuance of
shares under employee...
$280K
Net cash used in
investing activities
$1,757K
(1355.00%↑ Y/Y)
Net cash (used in)
provided by financing...
$136K
(-99.91%↓ Y/Y)
Canceled cashflow
$13K
Canceled cashflow
$144K
Net (decrease)
increase in cash, cash...
-$17,570K
(-114.89%↓ Y/Y)
Canceled cashflow
$1,893K
Share-based compensation
expense
$3,965K
(-39.64%↓ Y/Y)
Accrued expenses and
other current...
$2,974K
Accounts
payable-Nonrelated Party
$1,496K
(447.10%↑ Y/Y)
Non-cash lease expense
$101K
(339.13%↑ Y/Y)
Depreciation expense
$66K
(3200.00%↑ Y/Y)
Purchases of property and
equipment
$13K
(-90.71%↓ Y/Y)
Payment of deferred
offering costs
$144K
Net cash used in
operating activities
-$19,463K
(28.58%↑ Y/Y)
Canceled cashflow
$8,602K
Net loss
-$24,837K
Gain on sale of assets
$1,770K
Prepaid expenses and
other current assets
$1,013K
(-10.67%↓ Y/Y)
Other assets
$339K
(534.62%↑ Y/Y)
Operating lease liability
-$106K
(-857.14%↓ Y/Y)
Buy us a coffee
CRESCENT BIOPHARMA, INC. (CBIO)
CRESCENT BIOPHARMA, INC. (CBIO)